Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2012. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the vesting of conditional share awards granted in 2009 under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation transactions and dividend reinvestment details.
- Share Prices (15 February 2012): £14.21 per Ordinary Share; $44.48 per American Depositary Share (ADS).
- Dividend Reinvestment: Dividends on vested awards were reinvested at the prices noted above.
Material Changes
On 17 February 2012, the Remuneration Committee approved the vesting of 49% of the 2009 Performance Share Plan awards following a three-year performance period. Consequently, on 8 March 2012, specific numbers of Ordinary Shares and ADSs vested or lapsed for various directors and managers. The ex-dividend date for the fourth quarter 2011 and supplemental dividends was 15 February 2012.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is a regulatory disclosure of specific share transactions compliant with Disclosure and Transparency Rules 3.1.4R(1)(a).
Key Facts for Investor Verification
- Vesting Percentage: 49% of the 2009 Performance Share Plan awards vested for all listed individuals.
- Executive Director Activity: Sir Andrew Witty and Dr. M. Slaoui (Executive Directors) had significant share movements, with Witty vesting 4,780 Ordinary Shares and Slaoui vesting 709 ADSs.
- Transaction Date: The vesting and lapsing of shares occurred on 8 March 2012.
- Dividend Treatment: Dividends associated with the vested awards were automatically reinvested in additional shares rather than paid in cash.